US FDA approves Alnylam's drug for rare heart condition
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
STAT2h
Alnylam drug wins FDA approval for progressive heart disease
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Fierce Pharma1h
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...
BioPharma Dive2h
Alnylam drug gets long-awaited FDA approval in deadly heart disease
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
BioSpace6d
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...
Fierce Pharma1d
Pfizer enlists Elizabeth Banks for Gen X-focused pneumococcal vaccine push
In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new ...
Pfizer (NYSE:PFE) To Divest Entire 7 Percent Stake In Haleon Through Share Offering
Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...
Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge
Protalix Biotherapeutics (PLX) has gained investor’s attention, and reported a record revenue increase in its fiscal year 2024, primarily due ...
Oncology Nurse Advisor8d
FDA Approves New Combined Therapy for Relapsed or Refractory DLBCL
In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.
Alnylam wins FDA approval for rare heart disease drug
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability.